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OBJECTIVE—Vascular endothelial cells (VECs) downregu-
late their rate of glucose uptake in response to hyperglycemia
by decreasing the expression of their typical glucose trans-
porter GLUT-1. Hitherto, we discovered critical roles for the
protein calreticulin and the arachidonic acid–metabolizing enzyme
12-lipoxygenase in this autoregulatory process. The hypothesis that
4-hydroxydodeca-(2E,6Z)-dienal (4-HDDE), the peroxidation prod-
uct of 12-lipoxygenase, mediates this downregulatory mechanism
by activating peroxisome proliferator–activated receptor (PPAR) 
was investigated.
RESEARCH DESIGN AND METHODS—Effects of 4-HDDE
and PPAR on the glucose transport system and calreticulin
expression in primary bovine aortic endothelial cells were
evaluated by pharmacological and molecular interventions.
RESULTS—Using GW501516 (PPAR agonist) and GSK0660
(PPAR antagonist), we discovered that high-glucose–induced
downregulation of the glucose transport system in VECs is
mediated by PPAR. A PPAR-sensitive luciferase reporter assay
in VECs revealed that high glucose markedly increased luciferase
activity, while GSK0660 abolished it. High-performance liquid
chromatography analysis showed that high-glucose incubation
substantially elevated the generation of 4-HDDE in VECs. Treat-
ment of VECs, exposed to normal glucose, with 4-HDDE mim-
icked high glucose and downregulated the glucose transport
system and increased calreticulin expression. Like high glucose,
4-HDDE signiﬁcantly activated PPAR in cells overexpressing
human PPAR (hPPAR) but not hPPAR,- 1, or -2. Moreover,
silencing of PPAR prevented high-glucose–dependent alter-
ations in GLUT-1 and calreticulin expression. Finally, speciﬁc
binding of PPAR to a PPAR response element in the promoter
region of the calreticulin gene was identiﬁed by utilizing a
speciﬁc chromatin immunoprecipitation assay.
CONCLUSIONS—Collectively, our data show that 4-HDDE
plays a central role in the downregulation of glucose uptake in
VECs by activating PPAR. Diabetes 59:808–818, 2010
H
yperglycemia is a major and independent risk
factor in the development of cardiovascular
disease and atherosclerosis in diabetes (1,2).
Vascular endothelial cell (VEC) dysfunction
precedes the development of atherosclerotic plaques (3–
6). These adverse functions in VECs result from impaired
carbohydrate metabolism, mitochondrial dysfunction, ox-
idative stress, excessive protein glycation, malfolding of
proteins, and altered expression of various genes (3,7).
For reasons not well understood, some diabetic patients
never develop long-term vascular complications (8,9). We
discovered an autoregulatory mechanism that protected
VECs against deleterious effects of hyperglycemia by
downregulating the level of their principal glucose trans-
porter GLUT-1 mRNA and protein and its plasma membrane
abundance (10–12). We linked this protective mechanism
to an augmented expression of the enzyme 12-lipoxygen-
ase (12-LO), which produces 12-hydroxyeicosatetraenoic
acid (12-HETE) from arachidonic acid. Pharmacological
inhibition of 12-LO completely blocked this downregula-
tory interaction, suggesting a critical role for 12-HETE in
this process. We also found that GLUT-1 downregulation
resulted from destabilization and degradation of GLUT-1
mRNA via a speciﬁc interaction with the protein calreti-
culin (13), whose expression was signiﬁcantly increased in
VECs and blood vessels under hyperglycemic conditions
(13).
The 12-LO metabolite 12-hydroperoxyeicosatetraenoic
acid (12-HpETE) is effectively reduced by glutathione
peroxidase (GPx) to 12-HETE (14). Reactive oxygen spe-
cies (ROS), which are produced under hyperglycemic
conditions (7), inactivate GPx and slow this reaction. This
renders 12-HpETE susceptible to radical induced peroxi-
dation and a chain-breaking reaction to generate the
corresponding reactive hydroxyalkenal, 4-hydroxydodeca-
(2E,6 Z)-dienal (4-HDDE) (15,16).
High levels of 4-hydroxyalkenals are cytotoxic due to
covalent adduct formation with macromolecules. Yet,
these lipid peroxidation products function at low concen-
trations as signaling molecules (17,18). For instance, 4-hy-
droxy-2E-nonenal (4-HNE), the peroxidation product of
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peroxisome proliferator–activated receptor (PPAR)  in
3T3-L1 preadipocytes (19).
The present study aimed at investigating the hypothesis
that 12-HETE and/or 4-HDDE, the oxidation and peroxi-
dation products of 12-HpETE, respectively, interact with
PPAR and regulate calreticulin expression to operate the
downregulatory machinery of the glucose transport sys-
tem in VECs.
RESEARCH DESIGN AND METHODS
Glucose-free Dulbecco’s modiﬁed Eagle’s medium was from Life Technologies
(Grand Island, NY). Biological Industries (Beth-Haemek, Israel) supplied
antibiotics, bovine ﬁbronectin, FCS, and soybean trypsin inhibitor. Calbio-
chem (Darmstadt, Germany) supplied GW501516 and 4-HNE. 4-HDDE was
synthesized as described (16). Sigma-Aldrich (Rehovot, Israel) supplied
12-HETE, WY14643, baicalein, cytochalasin B, GSK0660, L-glucose, troglita-
zone, and the anti–-tubulin antibody. The following polyclonal antibodies
were used: rabbit anti-calreticulin (Stressgen Biotechnologies, Victoria, BC,
Canada); rabbit anti–GLUT-1 (courtesy of Dr. H.-G. Joost, the Institute of
Human Nutrition, Bergholz-Rehbru ¨cke, Germany); anti-(C terminus) GLUT-3
and -GLUT-4 (Millipore, Billerica, MA); anti-PPAR, -PPAR, and -PPAR
(Cayman Chemicals, Ann Arbor, MI); anti-PPAR (H-74; Santa Cruz Biotech-
nology, Santa Cruz, CA); and horseradish peroxidase–conjugated anti-rabbit
IgG (Jackson ImmunoResearch, West Grove, PA). Abcam (Cambridge, U.K.)
supplied the chromatin immunoprecipitation (ChIP) assay kit. American
Radiolabeled Chemicals (St. Louis, MO) supplied 2-[1,2-
3H(N)]deoxy-D-glu-
cose (1.48 TBq/mmol). Mirus Bio-Corporation (Madison, WI) supplied the
TransIT-LT1reagent and Biontex Laboratories (Munich, Germany) the Meta-
fectene. Promega (Madison, WI) supplied the dual-luciferase reporter assay
system, ligase, Pfu DNA polymerase, pGEM T-easy plasmid, random primers,
restriction enzymes, and RNA polymerase. RNasin was from TaKaRa (Tokyo,
Japan). Real-time PCR reagents were purchased from Applied Biosystems
(Carlsbad, CA). ReddyMix PCR Master was from Thermo Scientiﬁc (Epsom,
Surrey, U.K.). The PPAR small-interfering RNA (siRNA) was from Dharma-
con (Lafayette, CO). The pcDNA3 and pEGFP-N1 plasmids and the MCF10
cDNA library were kindly provided by Dr. R. Hertz and Dr. R. Reich,
respectively (The Hebrew University, Jerusalem, Israel). The pSVPORT1-
hRXR vector and the 3PPAR response element (PPRE)-TK-luciferase plas-
mid were donated by Dr. B.M. Spiegelman (Dana Farber Cancer Institute,
Boston, MA). The plasmids pCMX-hPPAR1 and pCMX-hPPAR2 and the
respective empty plasmids were kindly provided by Dr. R. Evans (Howard
Hughes Medical Institute, La Jolla, CA). The pSG5 and pSG5-hPPAR vectors
were prepared in Dr. B. Staels’ laboratory. All primers were synthesized by
Sigma-Aldrich (Rehovot, Israel). Organic solvents were from Frutarom (Haifa,
Israel) and Mallinckrodt Baker (Deventer, Holland).
Cell cultures. Primary cultures of bovine aortic endothelial cells were
prepared and characterized as described previously (20). EA.hy926 cells were
cultured and maintained as described (21).
Hexose uptake assay. The [H
3]dGlc uptake assay in VEC cultures was
conducted as previously described (22). The nonspeciﬁc [H
3]dGlc uptake that
was determined in the presence of 10 mol/l cytochalasin B in the uptake
mixture was 4% of the total uptake. Cell numbers were determined
microscopically in a hemocytometer following cell detachment with a trypsin-
EDTA solution for endothelial cells (Sigma-Aldrich, Rehovot, Israel). Soybean
trypsin inhibitor (50 g/ml) was used to stop the reaction. Trypan blue
exclusion tests showed 1–3% dead cells following trypsinization.
Western blot analyses. Cell lysates were prepared, and Western blot
analyses of GLUT-1 calreticulin, PPAR, and -tubulin were performed as
previously described (22) or according to the antibody suppliers’ protocols.
Cell surface biotinylation of VECs and determination of plasma membrane–
associated GLUT-1 were carried as described (23).
Real-time PCR analysis. RNA isolation, cDNA synthesis, and real-time PCR
analyses of calreticulin and GLUT-1 mRNA in VECs were performed as
described by Totary-Jain et al. (13), using the same primers. Both mRNA levels
were normalized to 18S rRNA.
Cell transient transfections. VEC cultures, at 60% conﬂuency, were
cotransfected with DNA complexed to TransIT-LT1reagent in 2 ml growth
medium, according to the manufacturer’s instructions. The DNA consisted
of 165 ng pSG5-hPPAR, pCMX-hPPAR1, pCMX-hPPAR2, pcDNA-hPPAR,o r
the corresponding empty plasmids. It also contained the following plasmids:
pSVPORT1-hRXR (82.5 ng), 3PPRE-TK-luciferase reporter (500 ng), the
renilla luciferase (100 ng), and pEGFP-N1 (82.5 ng). The latter served to assess
of the yield of transfection by ﬂuorescence microscopy (80%; excitation, 490
nm; emission, 515 nm). After 24 h, the cultures were washed, received fresh
medium, and incubated for additional 24 h. Fireﬂy luciferase–induced lumi-
nescence was determined with the dual-luciferase reporter assay in a Mithras
LB-940 luminometer and normalized to Renilla luciferase activity as an
internal control, according to the kit’s instructions (Berthold Technologies,
Bad Wilbad, Germany).
Extraction of polar lipids and high-performance liquid chromatography
analysis. Polar lipid extraction from culture media or plasma and high-
performance liquid chromatography (HPLC) analysis were performed accord-
ing to Zanardi et al. (24), with some modiﬁcations. Brieﬂy, VEC cultures in
15-cm plates were incubated for 24 h with serum-free media and the indicated
additions. The media were then collected, cleared by centrifugation, and
loaded on prewashed Supelclean LC-18 SPE tubes (6 ml/1gr; Supelco, Belle-
fonte, PA) and washed with 15 ml cold water and petroleum ether (boiling
range 40–60°C). The polar lipid fraction was then eluted with 3 ml cold
methanol, dried under N2, dissolved in 300 l cold methanol, ﬁltered through
a Teﬂon syringe ﬁlter (0.45 mol/l; National Scientiﬁc, Rockwood, TN), sealed
under N2, and kept at 70°C. HPLC analysis was performed in a Merck Hitachi
machine with a Supelcosil LC-18-DB column (5 mol/l particle size, 25 cm 
10 mm; Supelco, Bellefonte, PA) connected to an ultraviolet detector (295
nm). For 4-HDDE, the elution (1.0 ml/min) started with a gradient of
acetonitrile:water (42:58), ﬂowed by a linear gradient that progressed over 25
min to 100% acetonitrile. For 4-HNE detection, the initial ratio in the mixture
was 30:70. Pure 4-HDDE and 4-HNE were used to resolve their respective
peaks at 10.0 and 4.2 min. The recovery of the standards was 85–90%.
Clarity-Lite software was used to analyze and quantify HPLC data.
ChIP. VECs at 5.5 mmol/l glucose were transfected with pcDNA-hPPAR,
pSVPORT1-hRXR, and pEGFP-N1 plasmids, as described above, and incubated
for 24 h. The cells were then treated with 100 nmol/l of GW501516 or with DMSO
and incubated for additional 24 h. Cell lysates were then prepared, sonicated,
fractionated, and immunoprecipitated with anti-PPAR (H-74) and anti–histone
H3 (positive control, ab-1791; Abcam, Cambridge, U.K.) and taken for PCR with
speciﬁc primers, according to the protocol of the ChIP assay kit as described in
the online appendix (available at http://diabetes.diabetesjournals.org/cgi/
content/full/db09-1207/DC1).
PPAR silencing with siRNA. Subconﬂuent bovine aortic endothelial cul-
tures were transfected with 100 nmol/l of the siRNA 5	-AAAATGATGTCACT-
GAAGGGC-3	 targeted to bovine PPAR, using metafectene according to the
manufacturer’s instructions. Control cells were treated with metafectene only.
Cells were harvested 72 h after transfection, and lysates were prepared and
used for Western blot analyses.
Statistical analysis. Results are given as means 
 SE. Statistical analyses
were performed using the nonparametric Mann-Whitney test.
RESULTS
Effects of PPAR agonists on the rate of glucose
uptake in VECs. The potential role of PPAR,- ,o r-  in
the regulation of glucose uptake in VECs was elucidated
by studying the capacity of their respective selective
agonists, WY14643, troglitazone, and GW501516 (25), to
downregulate the rate of glucose uptake in VECs under
normal glucose levels (Fig. 1A). The control treatment (25
mmol/l glucose) shows the characteristic high-glucose–
induced 50% reduction in the rate of hexose uptake in
comparison to the 5.5 mmol/l glucose incubation (10).
GW501516, but not troglitazone or WY14643, mimicked
high glucose and comparably downregulated the uptake
rate in cells under normal glucose, indicating that only
PPAR participates in the downregulatory response. Max-
imal effect of GW501516 was obtained between 1 and 100
nmol/l and within 36–48 h (supplemental Fig. S1A and B,
which can be found in the online appendix. The vehicle
(DMSO) had no signiﬁcant effect on the rate of glucose
uptake.
Figure 1B shows that the PPAR antagonist GSK0660
(26) effectively prevented the downregulation of glucose
uptake induced by 25 mmol/l glucose in VECs, whereas the
basal high rate of glucose uptake in cells at 5.5 mmol/l
glucose was not altered. Supplemental Fig. S1C conﬁrms
the speciﬁcity and the competitive nature of GSK0660-
induced inhibition of PPAR.
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hypothesis that 12-LO metabolites and PPAR cooperate
in the downregulatory response. Fig. 1C shows that the
inhibition of 12-LO with baicalein prevented high-glucose–
induced downregulation of glucose uptake. Yet, GW501516
downregulated the uptake in the presence of baicalein. No
synergistic interactions between GSK0660 and baicalein in
high-glucose VEC cultures were found, suggesting that
12-LO and PPAR act in sequence (Fig. 1D). The cellular
content of PPAR was not altered by the ambient glucose,
GW501516, or baicalein (supplemental Fig. S2). Supple-
mental Fig. S3 indicates that the slight increase in the
osmotic pressure in the high-glucose–containing culture
medium had no effect on the glucose transport system.
GW501516 reduces GLUT-1 expression and plasma
membrane abundance in VECs. The data in Fig. 2A–C
show that GW501516 reduced GLUT-1 mRNA and protein
levels and plasma membrane abundance in cells exposed
to 5.5 mmol/l glucose to the downregulated levels induced
by the 25 mmol/l glucose incubation. Moreover, GW501516
also prevented baicalein-mediated upregulation of GLUT-1
expression and its subcellular distribution in cells exposed
to high glucose, thus linking 12-LO metabolites to PPAR
in the mechanism of the downregulation of GLUT-1 ex-
pression. Supplemental Fig. S4 shows that the cell content
of GLUT-3 and GLUT-4 in VECs was not altered by high
glucose or GW501516.
High glucose activates PPAR in VECs. The hypothesis
that high glucose levels activate PPAR was further inves-
tigated in VECs that were transfected with a PPRE-
luciferase reporter vector (3PPRE-TK-luciferase). Figure
3A shows a 1.5-fold increase in luciferase activity in cells
exposed to 25 mmol/l glucose in comparison with the
low-glucose incubation. GSK0660 abolished this stimula-
tory effect, suggesting a PPAR-dependent transcription of
the luciferase gene. The control experiment in supplemen-
tal Fig. S5 shows that GSK0660 fully inhibited GW501516-
induced transcription of luciferase in the same assay.
VECs overexpressing the various hPPAR isotypes (, 1,
2, or ), hRXR, and the PPRE-luciferase reporter expres-
sion plasmids were used. Control cells received the empty
plasmids. All four hPPAR isotypes were successfully over-
expressed (supplemental Fig. S6). Figure 3B shows that
high glucose increased luciferase activity 1.3- to 1.5-fold in
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FIG. 1. Activation of PPAR reduces the rate of hexose transport in VECs. Conﬂuent VEC cultures were exposed to 5.5 or 25 mmol/l glucose for
48 h. A: The 5.5 mmol/l cultures were treated without or with GW501516 (100 nmol/l), troglitazone (30 mol/l), or WY14643 (60 mol/l). B: Both
5.5 and 25 mmol/l glucose cultures were incubated for 48 h in the absence or presence of 1 mol/l of GSK0660. C: VEC cultures were incubated
at 5.5 or 25 mmol/l glucose and treated with GW501516 (100 nmol/l) and/or baicalein (80 mol/l), as indicated. The latter was present during the
last 10 h of incubation. D: VEC cultures were incubated at 5.5 or 25 mmol/l glucose for 48 h without or with GSK0660 (1 mol/l, 48 h) and or
baicalein (80 mol/l, last 10 h). At the end of incubations, cells were washed and taken for the standard [
3H]dGlc uptake assay. The respective
rates of dGlc uptake at 5.5 mmol/l glucose (A:7 0 8, B:5 4 5, C:9 6 1, and D:6 5 8 pmol dGlc/10
6 cells/min) were taken as 100%. *P < 0.05
for differences from the respective controls (n  4).
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effect, which was also found in VECs transfected with
the reporter construct only (Fig. 3A), is attributed to the
activation of an endogenous PPAR by high glucose. The
observation that high glucose markedly increased lucif-
erase activity (2.6-fold) only in cells overexpressing
hPPAR suggests that PPAR is this endogenous receptor
that is activated under hyperglycemic conditions.
12-HETE activates PPAR in VECs. High glucose in-
creases 12-LO expression in VECs and consequently aug-
ments the synthesis and secretion of 12-HETE in VECs
(10). When tested in the present luciferase reporter assay,
12-HETE (3 mol/l, 24 h) increased luciferase activity
1.70 
 0.03-fold (n  3) in hPPAR-expressing VECs, in
comparison with control cells. This is most likely an
underestimated value because 12-HETE is prone to a rapid
oxidation in the open air (t1/2  10–12 min [10]). This
degradation is most likely the reason for the failure of
exogenously added 12-HETE to downregulate the rate of
hexose transport in VEC cultures (10).
4-HDDE activates PPAR and modulates the rate of
hexose transport in VECs. Radical-induced peroxida-
tion of the 12-LO and 15-LO products, 12-HpETE and
15-HpETE, respectively, generate the corresponding bio-
logically active aldehydes 4-HDDE and 4-HNE (16,18). It
has been reported that 15-HETE and 4-HNE activate
PPAR (19). We asked whether 4-HDDE could activate
PPAR in VECs. Figure 4A shows a remarkable 4.3 

0.1-fold increase in hPPAR-dependent, but not hPPAR-,
hPPAR1-, or hPPAR2-dependent, stimulation of the re-
porter luciferase activity in cells treated with 100 nmol/l
4-HDDE. Like high glucose and GW501516 (Figs. 1 and 2),
4-HDDE (50 nmol/l) signiﬁcantly reduced the rate of
hexose uptake (Fig. 4B) and the cell content of GLUT-1
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FIG. 2. GW501516 decreases the level of GLUT-1 mRNA and protein as well as its plasma membrane abundance in VECs.VEC cultures were treated
with GW501516 and baicalein as described under the legend to Fig. 1C. Cells were then processed and taken for real-time PCR analysis of GLUT-1
mRNA (A), Western blot analysis of GLUT-1 (B), or for cell surface biotinylation to determine the relative plasma membrane (PM) abundance
of GLUT-1 (C). *P < 0.05, for differences from the respective controls (n  4).
Y. RIAHI AND ASSOCIATES
diabetes.diabetesjournals.org DIABETES, VOL. 59, APRIL 2010 811mRNA and protein (Fig. 4C and D) in VECs under 5.5
mmol/l glucose. The upregulatory effect induced by baica-
lein in high-glucose cultures was also reversed by 4-HDDE
(Fig. 4B–D). The inhibitor GSK0660 abolished 4-HDDE–
induced downregulation of the rate of hexose transport in
VECs exposed to 5.5 mmol/l glucose (Fig. 4E). The con-
centrations of 4-HDDE used in these experiments (50–100
nmol/l) did not compromise VEC viability (supplemental
Fig. S7). The similar effects of 4-HDDE and GW501516
suggest that the former is an endogenous ligand for
PPAR.
Extraction of polar lipid and HPLC analyses were per-
formed to measure 4-HDDE production in VECs exposed
to 2 or 25 mmol/l glucose. High glucose increased the
secretion of 4-HDDE 5.9 
 3.1-fold higher than at the
low-glucose incubation (Fig. 5A), while baicalein blocked
this effect, conﬁrming that 4-HDDE is indeed derived from
a 12-LO metabolite. The initial step in lipid peroxidation is
a hydrogen atom abstraction by ROS (16); therefore,
antioxidants can attenuate this process (27). Figure 5A
and B shows that the antioxidant N-acetylcysteine com-
pletely prevented high-glucose–dependent generation of
4-HDDE and the downregulation of hexose transport. Fig.
5C depicts a comparable increase in 4-HDDE generation in
the plasma of hyperglycemic Zucker diabetic rats (details
on the animals are given in the online appendix). Repre-
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medium and plasma extracts are shown in supplemental
Fig. S8. Noteworthy, similar HPLC analyses of the same
extracts did not reveal signiﬁcant differences in 4-HNE
levels between the low- and high-glucose incubations
(data not shown).
PPAR regulates calreticulin expression in VECs.
Calreticulin, whose expression is signiﬁcantly increased in
VECs exposed to high glucose, destabilizes GLUT-1 mRNA
(13). Figures 6A–D conﬁrm previous ﬁndings (13) on
high-glucose–induced increased expression of calreticulin
mRNA and protein levels in VECs under high glucose. This
effect was eliminated in the presence of baicalein, suggest-
ing that 12-LO metabolites participate in the regulation of
calreticulin expression. Both GW501516 (Figs. 6A and B)
and 4-HDDE (Figs. 6C and D) increased the expression
levels of calreticulin mRNA and protein in VECs exposed
to 5.5 mmol/l glucose. Both compounds also reversed the
effect of baicalein and restored calreticulin mRNA and
protein expression to the levels measured under the
high-glucose incubation. Inversely, the inhibition of
PPAR with GSK0660 prevented high-glucose–induced in-
creased expression of calreticulin in VECs (Fig. 6E). These
data suggest that PPAR participates in the regulation of
calreticulin expression in VECs.
The potential of PPAR to interact with PPREs in the
calreticulin gene was determined. We identiﬁed four PPRE
sequences in the promoter region of the bovine calreticu-
lin gene (3,000 bp upstream of the coding sequence)
located at 5	-1,710–1,732, 1964–1986, 2,139–2,161, and
2,255–2,277 bp. The ChIP assay was used to determine
whether PPAR binds to these elements. DNA samples
from VECs overexpressing hPPAR and hRXR and treated
with 100 nmol/l GW501516 or the vehicle were immuno-
precipitated with an anti-PPAR antibody and taken for
the respective PCR analyses. Figure 6F depicts a speciﬁc
binding interaction of PPAR with the PPRE located at
5	-2139–2,161 bp in this promoter region.
PPAR expression in VECs was silenced with a speciﬁc
siRNA, and the expression levels of calreticulin and
GLUT-1 were determined (Fig. 7). A 50–60% reduction in
PPAR expression in VECs exposed to 25 mmol/l led to a
30–40% decrease in the content of calreticulin and a
30–40% increase in GLUT-1 expression in comparison
with the respective controls. Similar effects were observed
in VECs exposed to 5.5 mmol/l glucose (data not shown).
Finally, we used the EA.hy926 cell line to determine
whether human-derived endothelial cells regulate the glu-
cose transport system like bovine VECs. This cell line,
which was derived from primary cultures of human um-
bilical cord vascular endothelial cells (21), has been
shown in many studies to preserve markers and functions
of the primary cells. High glucose downregulated the rate
of glucose transport and total GLUT-1 level and increased
calreticulin expression in a PPAR-dependent manner in
these cells in (supplemental Fig. S9A–C). Exposure of
EA.hy926 cells to normal glucose conditions and 4-HDDE
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hPPAR expression vectors and other plasmids and incubated as de-
scribed in the legend to Fig. 3B. Cultures received the indicated
concentration of 4-HDDE during the last 24 h of incubation. The cells
were then lysed, and the relative luciferase activity was determined and
standardized to the untreated control. *P < 0.05, for differences from
the untreated cells (n  4). B–D: Conﬂuent VEC cultures were incu-
bated for 48 h with 5.5 or 25 mmol/l glucose in the absence or presence of
4-HDDE (50 nmol/l). Baicalein (80 mol/l) was added to cultures for the
last 10 h of incubation. The cells were then washed, lysed, and taken for
the standard [
3H]dGlc uptake assay (B), real-time PCR analysis of GLUT-1
mRNA (C), or Western blot analysis of total GLUT-1 (D).
The rate of dGlc uptake at 5.5 mmol/l glucose (79  3 pmol dGlc/10
6
cells/min) was taken as 100%. *P < 0.05, for differences from the
respective controls (n  4). E: Conﬂuent VEC cultures were incubated
at 5.5 or 25 mmol/l glucose for 48 h in the absence or presence of
4-HDDE (50 nmol/l) and or GSK0660 (1 mol/l), as indicated. At the
end of incubation the cells were washed and taken for the standard
[
3H]dGlc uptake assay. The rate of dGlc uptake at 5.5 mmol/l glucose
(65  8 pmol/10
6 cells/min) was taken as 100%. *P < 0.05, for
differences from the respective controls (n  4).
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of hexose transport, while GSK0660 prevented this effect
(Fig. S9D). These data suggest that both bovine and human
VECs use a similar mechanism to downregulate the glu-
cose transport system.
DISCUSSION
Two key factors that mediate high-glucose–induced
downregulation of the glucose transport system in bo-
vine aortic endothelial cells and in the human-derived
EA.hy926 cells have been identiﬁed: the lipid peroxida-
tion product 4-HDDE and its cognate nuclear receptor
PPAR. The latter increases the expression of the
protein calreticulin that was shown before to destabilize
GLUT-1 mRNA (13).
The augmented production of 4-HDDE results from
high-glucose–induced 12-LO expression and activity and
glucose-derived ROS. The mechanism responsible for the
increased expression of 12-LO is not yet known. Numer-
ous studies have proven that hyperglycemia promotes the
generation of ROS (3,7). We showed before an augmented
production of ROS in bovine aortic endothelial cell pri-
mary cultures under high-glucose conditions (28). Two
observations conﬁrm the role of ROS in the generation of
4-HDDE from 12-LO metabolites. First, the inhibition of
12-LO activity with baicalein signiﬁcantly reduced 4-HDDE
secretion from VECs under high-glucose conditions. Sec-
ond, the antioxidant N-acetylcysteine blocked 4-HDDE
production in VECs under similar conditions. The capacity
of baicalein and N-acetylcysteine to prevent high-glucose–
induced downregulation of glucose uptake is attributed to
the impeded production of 4-HDDE. Collectively, these
data indicate that high-glucose–induced overexpression of
12-LO and overproduction of ROS underlie the augmented
generation of 4-HDDE.
The physiological, pathophysiological, or cytotoxic ef-
fects of 4-hydroxyalkenals depend on their absolute con-
centrations. Esterbauer et al. (18) concluded that at
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1 pmol dGlc/10
6 cells/min) was taken as 100%. P < 0.05, for
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C: The levels of 4-HDDE in extracts of plasma samples from
ZDF and normoglycemic rats (respective blood glucose
levels were 354  28 and 92  6 mg/dl, n  4) were
determined by HPLC, and the value of the average levels of
4-HDDE in the plasma of the nondiabetic rats was taken as
1 unit. *P < 0.05, for differences from the respective
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fects due to its chemical reactivity and the formation of
stable adducts with macromolecules. Bacot et al. (16,29)
linked 4-hydroxyalkenals to membrane disorders due to
the formation of stable adducts with ethanolamine phos-
pholipids. It is important to emphasize that the effective
concentrations of 4-HDDE (1–100 nmol/l) used in the
present study were not cytotoxic to VECs. The present
study shows that a moderate production of ROS, sufﬁcient
to initiate the generation of nontoxic levels of 4-HDDE in
VECs, is required for an effective cellular defense against
harmful effects of hyperglycemia. Notwithstanding, an
excessive and uncontrolled oxidative stress in VECs may
lead to the production of cytotoxic levels of 4-hydroxyalk-
enals. Many studies have indeed suggested that an excessive
4-hydroxyalkenal production underlies various pathological
conditions (30,31).
Tissue-speciﬁc production of 4-hydroxyalkenals corre-
lates with the particular pattern of expression of the
various lipoxygenases and synthesis of their correspond-
ing HpETEs. For example, the peroxidation products
4-HHE and 4-HNE, but not 4-HDDE, were found in the
diabetic rat retina, which predominantly expresses 5-LO
and 15-LO (29,32). Our present ﬁndings on 4-HDDE– and
PPAR-dependent downregulation of the glucose trans-
port system in human VECs correlate well with previous
reports on high-glucose–induced expression of 12-LO in
human VECs (4).
We found before that high glucose levels increased
the expression of 12-LO but not of 15-LO in VECs (10).
Subsequently, high glucose promotes the generation of
4-HDDE from 12-HpETE but not of 4-HNE, which is
derived from 15-HpETE. Nevertheless, it has been
shown before that 4-HNE also activates PPAR (19).
Using the luciferase reporter assay we found that the
potency of 4-HDDE to activate the system was 200-fold
higher than that of 4-HNE (50 nmol/l vs. 10 mol/l).
These disparate potencies suggest that the binding
afﬁnity of 4-HDDE to the ligand binding domain (LBD)
in PPAR is markedly higher than that of 4-HNE. This
may reﬂect the increased hydrophobicity of the 4-HDDE
in comparison with 4-HNE (logP values 3.48 and 2.45,
respectively, calculated with the Molinspiration Che-
moinformatics software). X-ray analyses of crystal
structures of the PPAR LBD identiﬁed a network of
hydrogen bonds with His
413,T y r
427,H i s
287, and Thr
253
that are involved in the binding interaction of eicosap-
entanoic acid (33). His
413 has also been implicated in a
hydrogen-bonding interaction with the 4-hydroxy group
of 4-HNE (19). The speciﬁc molecular binding kinetics
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FIG. 6. PPAR regulates calreticulin expression in VECs.
Conﬂuent VEC cultures were treated with GW501516
(100 nmol/l) (A and B) or 4-HDDE (50 nmol/l) (C and D)
as described in the legends to Figs. 1A and 4B, respec-
tively. Cells were then processed for real-time PCR
analysis of calreticulin mRNA (A and C) or Western blot
analysis of calreticulin (B and D). *P < 0.05, for differ-
ences from the respective controls (n  4). E: Conﬂuent
VEC cultures were treated with GSK0660 (1 mol/l) as
indicated for 48 h. At the end of incubation the cells were
processed for Western blot analysis of calreticulin. F:
VEC overexpressing hPPAR and hRXR, which were pre-
pared as described in the legend to Fig. 3B, were treated
with GW501516 or the vehicle and processed for PPAR-
ChIP analysis as described in RESEARCH DESIGN AND
METHODS.
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analyzed.
Many studies over the last decade have assigned PPAR
key metabolic regulatory functions (34). For instance, it
augments lipogenesis and glycolysis in the liver (35),
increases fatty acid oxidation in adipocytes (36), and
increases oxidative metabolism in skeletal muscles
(37,38). Of interest are recent studies on protective effects
of PPAR ligands against the development of atheroscle-
rosis by regulating lipid homeostasis, decreasing the
expression of inﬂammatory genes, and attenuating macro-
phage migration. We speculate that 4-HDDE–activated
PPAR may mediate some of these effects.
This study links PPAR activation to the transcription of
the calreticulin gene. We have previously found that the
ﬁnal step in the downregulation of GLUT-1 expression in
VECs is calreticulin-mediated destabilization of the trans-
porter mRNA (13). Because calreticulin is a multifunc-
tional protein (39), it is feasible that PPAR-regulated
transcription of calreticulin may affect some of these
functions (e.g., calcium storage, cell adhesion, chaperon-
ing of malfolded proteins). The present study has identi-
ﬁed a PPRE in the promoter of the calreticulin gene that
seems to interact with PPAR. The precise nature of this
interaction and its contribution to the assembly of an
active transcription complex of calreticulin need further
investigations.
Recently, Gross and Staels (40) have stressed the need
for the development of novel PPAR and PPAR agonists
for the treatment of type 2 diabetes. We suggest that novel
PPAR agonists may reduce the risk of dysfunctional
endothelial cells in blood vessels by downregulating the
rate of glucose uptake and protecting them from the
deleterious effects of an increased inﬂux of glucose.
Clearly, 4-HDDE is not considered a potential pharmaco-
logical agonist due to its severe side effects when present
at concentrations that allow irreversible covalent binding
and cross-linking of macromolecules. Nonetheless, molec-
ular and chemical analyses of the interaction of 4-HDDE
with the PPAR LBD may provide a platform for a rational
design of potent and safe PPAR agonists.
Finally, our previous and current ﬁndings on the auto-
regulation of the glucose transport system in VECs are
summarized in the model shown in Fig. 8. High glucose
levels increase the expression of the arachidonic acid,
metabolizing enzyme 12-LO, which leads to an augmented
production of 12-HpETE and its immediate metabolite
12-HETE. Concomitantly, high-glucose–derived ROS ini-
tiates the peroxidation of 12-HpETE and the generation of
4-HDDE. This molecule, and possibly 12-HETE, interact
speciﬁcally with and activate PPAR, which in turn binds
to a PPRE in the promoter region of the calreticulin gene
and augments its transcription. Calreticulin binds to a
speciﬁc 10-nucleotide sequence located in the 3	-untrans-
lated region of GLUT-1 mRNA, destabilizing and rendering
it susceptible to degradation. Consequently, the cell con-
tent of GLUT-1 protein and its plasma membrane abun-
dance are signiﬁcantly reduced and downregulation of
glucose uptake ensues.
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